Tiziana Life Sciences plc – PDMR dealings June 25, 2019 – Posted in: Tiziana Life Sciences (TILS) – Tags: anti-CD3, autoimmune, Crohn's & Colitis 360, crohns disease, Foralumab, inflammatory diseases, Kunwar Shailubhai, Monoclonal Antibody, Monoclonal Antibody Platform, neurodegenerative disease, Severe Ulcerative Colitis Patients, tils, Tiziana Life Sciences
New York/London, 25 June 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on 24 June 2019, Panetta Partners Limited, an entity closely associated with Gabriele Cerrone, Executive Chairman, bought ordinary shares of nominal value 3p each in the capital of the Company, as set out below, following prior consultation with the Takeover Panel in relation to Note 11 to Rule 9.1 of the City Code on Takeovers and Mergers.
The information set out below is provided in accordance with the requirements of Regulation 19(3) of the EU Market Abuse Regulation No 596/2014:
| 1. | Details of PDMR / person closely associated | |||
| a) | Name | Gabriele Cerrone/Panetta Partners Limited | ||
| 2. | Reason for the notification: On market acquisition | |||
| a) | Position / status | Executive Chairman | ||
| b) | Initial notification /amendment | Initial notification | ||
| 3. | Details of the issuer | |||
| a) | Name | Tiziana Life Sciences plc | ||
| b) | LEI | 213800CED47HI8PIOB36 | ||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
| a) | Description of the financial instrument | Ordinary Shares of nominal value 3p each | ||
| b) | Identification code of the Financial Instrument | GB00BKWNZY55 | ||
| c) | Nature of the transaction | On market acquisition of ordinary shares | ||
| d) | Price(s) and volume(s) |
|
||
| e) | Aggregated information
– Aggregated volume – Price |
7,500 £5,625
|
||
| f) | Date of the transaction | 24 June 2019 | ||
| g) | Place of the transaction | XLON | ||
As a result of this transaction Mr Cerrone’s interests in the underlying ordinary shares of the Company increases from 64,248,425 (47.080%) to 64,255,925 (47.086%). Mr Cerrone’s interests in the ordinary shares of the Company are based on a holding of 63,680,404 ordinary shares held by Planwise Limited and voting rights in respect of 575,521 ordinary shares held by Panetta Partners Limited (as shares and via ADSs). Mr Cerrone is considered beneficially interested in the holdings of Panetta Partners Limited and Planwise Limited.
For more information go to http://www.tizianalifesciences.com
Contacts:
|
Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder
|
+44 (0)20 7493 2853 |
| Cairn Financial Advisers LLP (Nominated adviser)
Liam Murray / Jo Turner |
+44 (0)20 7213 0883 |
| Stockdale Securities (Broker)
Antonio Bossi / Andy Crossley
|
+44 (0)20 7601 6100 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END